Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENTA Stock Forecast 2026-2027
$13.24
Current Price
$384.22M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ENTA Price Targets
+51.1%
To High Target of $20.00
+51.1%
To Median Target of $20.00
-9.4%
To Low Target of $12.00
ENTA Price Momentum
-9.0%
1 Week Change
+5.8%
1 Month Change
+140.7%
1 Year Change
-16.0%
Year-to-Date Change
-22.8%
From 52W High of $17.15
+166.9%
From 52W Low of $4.96
📊 TOP ANALYST CALLS
Did ENTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enanta Pharmaceuticals is one of their latest high-conviction picks.
Latest ENTA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ENTA has a bullish consensus with a median price target of $20.00 (ranging from $12.00 to $20.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $13.24, the median forecast implies a 51.1% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 51.1% upside. Conversely, the most conservative target is provided by Liisa Bayko at Evercore ISI Group, suggesting a 9.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTA Analyst Ratings
4
Buy
1
Hold
0
Sell
ENTA Price Target Range
Low
$12.00
Average
$20.00
High
$20.00
Current: $13.24
Latest ENTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $20.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $20.00 |
| Nov 14, 2025 | JP Morgan | Anupam Rama | Overweight | Initiates | $17.00 |
| Oct 1, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Sep 30, 2025 | WestPark Capital | Ed Arce | Buy | Maintains | $28.00 |
| Sep 15, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $12.00 |
| Sep 2, 2025 | WestPark Capital | Ed Arce | Buy | Initiates | $24.00 |
| Aug 12, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $25.00 |
| Jul 28, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $20.00 |
| Jun 3, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $24.00 |
| May 14, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $18.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $18.00 |
| Nov 26, 2024 | Baird | Brian Skorney | Outperform | Maintains | $20.00 |
| Nov 26, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $21.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $27.00 |
| Oct 9, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Sep 27, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $22.00 |
| Aug 6, 2024 | JP Morgan | Eric Joseph | Underweight | Maintains | $10.00 |
Enanta Pharmaceuticals Inc. (ENTA) Competitors
The following stocks are similar to Enanta Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ENTA
Enanta Pharmaceuticals
mkt cap
406.56M
Enanta Pharmaceuticals Inc. (ENTA) Financial Data
Enanta Pharmaceuticals Inc. has a market capitalization of $384.22M with a P/E ratio of -3.4x. The company generates $66.98M in trailing twelve-month revenue with a -106.8% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of -60.5% and return on equity of -60.0%.
Valuation Metrics
Market Cap
$384.22M
Enterprise Value
$413.90M
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
6.1x
Growth & Margins
Revenue Growth (YoY)
+9.8%
Gross Margin
N/A
Operating Margin
-60.5%
Net Margin
-106.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+48.4%
Current Ratio
4.4x
Debt/Equity
152.6x
ROE
-60.0%
ROA
-13.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enanta Pharmaceuticals Inc. (ENTA) Business Model
About Enanta Pharmaceuticals Inc.
What They Do
Develops small molecule drugs for viral infections.
Business Model
Enanta Pharmaceuticals generates revenue through the discovery and development of innovative drug candidates, particularly for viral infections and liver diseases. The company partners with major pharmaceutical firms for commercialization, notably in hepatitis C treatments, allowing it to capitalize on its research and development efforts.
Additional Information
Based in Watertown, Massachusetts, Enanta operates in a competitive biotech landscape, utilizing its expertise in medicinal chemistry to address significant global health challenges. Its robust pipeline and focus on antiviral therapies position it as a key player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Dr. Jay R. Luly Ph.D.
Country
United States
IPO Year
2013
Website
www.enanta.comEnanta Pharmaceuticals Inc. (ENTA) Latest News & Analysis
Latest News
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) has initiated a Phase 1 clinical trial for EDP-978, an oral KIT inhibitor targeting urticaria and mast cell-driven diseases.
Why It Matters
Enanta Pharmaceuticals' Phase 1 trial of EDP-978 signals progress in drug development, potentially increasing its market value and attracting investor interest in a promising therapeutic area.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that data on its RSV treatment, zelicapavir, has been accepted for two presentations at the ESCMID conference in April 2026.
Why It Matters
Enanta's acceptance of data on zelicapavir for RSV treatment at a major conference could enhance its credibility, attract investor interest, and influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) will present preclinical data on its STAT6 inhibitor program at IMMUNOLOGY2026, scheduled for April 15-19, 2026, in Boston.
Why It Matters
Enanta Pharmaceuticals' presentation of preclinical data on its STAT6 inhibitor program at a major immunology conference could signal potential advancements and attract investor interest in its drug development pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026, at 10:45 a.m. ET. A live webcast will be available online.
Why It Matters
Management's participation in a prominent conference signals potential insights into Enanta's drug development progress, which could influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in its earnings prospects, potentially boosting the stock price.
Why It Matters
The upgrade to Zacks Rank #2 signals improved earnings outlook for Enanta Pharmaceuticals, potentially boosting investor confidence and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) will present preclinical data for EDP-978, a KIT inhibitor for Type 2 immune diseases, at the 2026 AAAAI Annual Meeting.
Why It Matters
Enanta Pharmaceuticals' presentation of EDP-978 preclinical data at a major allergy conference could indicate potential breakthroughs in treatment, impacting future stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ENTA Stock
What is Enanta Pharmaceuticals Inc.'s (ENTA) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Enanta Pharmaceuticals Inc. (ENTA) has a median price target of $20.00. The highest price target is $20.00 and the lowest is $12.00.
Is ENTA stock a good investment in 2026?
According to current analyst ratings, ENTA has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENTA stock?
Wall Street analysts predict ENTA stock could reach $20.00 in the next 12 months. This represents a 51.1% increase from the current price of $13.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enanta Pharmaceuticals Inc.'s business model?
Enanta Pharmaceuticals generates revenue through the discovery and development of innovative drug candidates, particularly for viral infections and liver diseases. The company partners with major pharmaceutical firms for commercialization, notably in hepatitis C treatments, allowing it to capitalize on its research and development efforts.
What is the highest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The highest price target for ENTA is $20.00 from Brandon Folkes at HC Wainwright & Co., which represents a 51.1% increase from the current price of $13.24.
What is the lowest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The lowest price target for ENTA is $12.00 from Liisa Bayko at Evercore ISI Group, which represents a -9.4% decrease from the current price of $13.24.
What is the overall ENTA consensus from analysts for Enanta Pharmaceuticals Inc.?
The overall analyst consensus for ENTA is bullish. Out of 15 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ENTA stock price projections?
Stock price projections, including those for Enanta Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 8:03 AM UTC